TWD 57.2
(-5.61%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 828.57 Million TWD | 31.34% |
2022 | 630.86 Million TWD | -28.78% |
2021 | 885.81 Million TWD | 25.57% |
2020 | 705.44 Million TWD | -13.29% |
2019 | 813.6 Million TWD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 753.68 Million TWD | -6.15% |
2024 Q1 | 803.06 Million TWD | -3.08% |
2023 Q3 | 887.5 Million TWD | -6.56% |
2023 Q2 | 949.76 Million TWD | 66.41% |
2023 Q4 | 828.57 Million TWD | -6.64% |
2023 Q1 | 570.75 Million TWD | -9.53% |
2022 Q4 | 630.86 Million TWD | 0.0% |
2022 FY | 630.86 Million TWD | -28.78% |
2021 FY | 885.81 Million TWD | 25.57% |
2020 FY | 705.44 Million TWD | -13.29% |
2019 FY | 813.6 Million TWD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Apex Biotechnology Corp. | 2.29 Billion TWD | 63.928% |
Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | 86.745% |
Panion & Bf Biotech Inc. | 3.23 Billion TWD | 74.389% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | 83.979% |
GenMont Biotech Incorporation | 1.65 Billion TWD | 49.88% |
Abnova (Taiwan) Corporation | 1.35 Billion TWD | 38.884% |
Adimmune Corporation | 9.48 Billion TWD | 91.264% |
Tanvex BioPharma, Inc. | 2.76 Billion TWD | 70.016% |
Polaris Group | 9.09 Billion TWD | 90.893% |
UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -20.795% |
PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | 41.574% |